Latest Period
Q2 2026
Security Snapshot
vTv Therapeutics Inc. - Class A Common Stock, par value $0.01 per share (VTVT) Institutional Ownership
CUSIP: 918385204
13F Institutional Holders and Ownership History from Q3 2023 to Q2 2026
Institutions Reporting
44
Shares (Excl. Options)
1,607,142
Price
$37.65
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Class A Common Stock, par value $0.01 per share
- Symbol
- VTVT on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 1,607,142
- Total 13F value
- $60,509,590
- Portfolio coverage rank
- 0%
- Share change
- +118,091
- Value change
- +$4,360,121
- Number of holders
- 44
- Underlying class
- Class A Common Stock ("Common Stock")
- Shares outstanding
- 3,911,217
- SEC-reported price per share
- $32.38
- Insider filing price
- $32.38
Latest holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- VTVT - vTv Therapeutics Inc. - Class A Common Stock, par value $0.01 per share is tracked under CUSIP 918385204.
- 44 institutions reported positions in Q2 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 35 to 44 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $58,986,362 to $60,509,590.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 44 institutions filings for Q2 2026.
Security key
918385204
Latest holder period
Q2 2026
13F holders
44
13D/G owners
4
CIK / CUSIP context first
Open Q2 2026 holders
VTVT full holder history
vTv Therapeutics Inc. SEC filings
vTv Therapeutics Inc. company facts
vTv Therapeutics Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 918385204:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
VTVT
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Samsara BioCapital, L.P. | 9.9% | 0% | $12,001,117 | +$1,803,961 | 403,942 | +18% | Srinivas Akkaraju | 08 Dec 2025 |
| Invus Global Management, LLC | 9.4% | -5.9% | $9,179,310 | +$1,051,154 | 393,098 | +13% | Raymond Debbane | 30 Sep 2025 |
| Trails Edge Capital Partners, LP | 9.9% | $5,108,040 | 340,536 | Trails Edge Capital Partners, LP | 29 Aug 2025 | |||
| MILLENNIUM MANAGEMENT LLC | 6.9% | +20% | $10,160,756 | +$1,686,758 | 269,874 | +20% | Millennium Management LLC | 30 Jun 2026 |
As of 30 Jun 2026, 44 institutional investors reported holding 1,607,142 shares of vTv Therapeutics Inc. - Class A Common Stock, par value $0.01 per share (VTVT). This represents 41% of the company’s total 3,911,217 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
41%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| SAMSARA BIOCAPITAL, LLC | 7.6% | 298,496 | 0% | 0.92% | $11,238,374 |
| MILLENNIUM MANAGEMENT LLC | 6.9% | 269,874 | +31% | 0.01% | $10,160,756 |
| FMR LLC | 6.7% | 260,391 | 0% | 0% | $9,803,721 |
| Siren, L.L.C. | 4.2% | 163,000 | 0% | 0.12% | $6,136,950 |
| BAKER BROS. ADVISORS LP | 3.8% | 148,314 | 0% | 0.03% | $5,584,022 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.4% | 94,463 | -13% | 0% | $3,556,532 |
| Trails Edge Capital Partners, LP | 2.2% | 85,192 | -39% | 0.51% | $3,207,479 |
| Aisling Capital Management LP | 1.3% | 50,000 | 0.4% | $1,882,500 | |
| MARSHALL WACE, LLP | 1% | 39,560 | +195% | 0% | $1,489,435 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.83% | 32,470 | -1.3% | 0% | $1,223,392 |
| RENAISSANCE TECHNOLOGIES LLC | 0.45% | 17,454 | 0% | $657,143 | |
| VANGUARD FIDUCIARY TRUST CO | 0.42% | 16,239 | +0.7% | 0% | $611,398 |
| BlackRock, Inc. | 0.38% | 14,731 | +17% | 0% | $554,622 |
| JANE STREET GROUP, LLC | 0.35% | 13,703 | 0% | $515,918 | |
| STATE STREET CORP | 0.31% | 12,266 | +15% | 0% | $461,815 |
| TWO SIGMA INVESTMENTS, LP | 0.29% | 11,486 | 0% | $432,448 | |
| Verdad Advisers, LP | 0.23% | 8,996 | 0.32% | $338,699 | |
| Integrated Quantitative Investments LLC | 0.21% | 8,210 | 0.05% | $309,106 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.21% | 8,023 | 0% | $302,066 | |
| Quadrature Capital Ltd | 0.16% | 6,305 | 0% | $237,383 | |
| Trexquant Investment LP | 0.16% | 6,240 | 0% | $234,936 | |
| NORTHERN TRUST CORP | 0.16% | 6,123 | -66% | 0% | $230,531 |
| Pathstone Holdings, LLC | 0.16% | 6,073 | 0% | 0% | $228,664 |
| Point72 Asset Management, L.P. | 0.15% | 5,947 | 0% | $223,905 | |
| HRT FINANCIAL LP | 0.15% | 5,923 | 0% | $223,000 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
12
Latest
Q2 2026
Rows shown
1-12 of 12
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 1,607,142 | $60,509,590 | +$4,360,121 | $37.65 | 44 |
| 2026 Q1 | 1,487,273 | $58,986,362 | +$6,374,514 | $39.66 | 35 |
| 2025 Q4 | 1,283,622 | $51,331,670 | +$2,953,481 | $39.99 | 27 |
| 2025 Q3 | 988,279 | $23,052,921 | +$9,364,357 | $23.35 | 23 |
| 2025 Q2 | 587,143 | $8,742,344 | +$226,154 | $15.00 | 21 |
| 2025 Q1 | 571,712 | $9,902,095 | +$353,201 | $17.32 | 20 |
| 2024 Q4 | 551,416 | $7,570,090 | +$133,643 | $13.81 | 17 |
| 2024 Q3 | 542,324 | $7,337,088 | +$2,516,893 | $13.56 | 20 |
| 2024 Q2 | 348,140 | $6,148,038 | +$252,272 | $17.66 | 19 |
| 2024 Q1 | 333,650 | $7,850,341 | +$6,240,904 | $23.53 | 19 |
| 2023 Q4 | 68,620 | $788,715 | +$781,835 | $11.50 | 14 |
| 2023 Q3 | 600 | $287 | +$287 | $0.48 | 1 |